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Abstract
One of the critical events that regulates muscle cell differentiation is the replacement of the lamin B receptor (LBR)-
tether with the lamin A/C (LMNA)-tether to remodel transcription and induce differentiation-specific genes. Here, we
report that localization and activity of the LBR-tether are crucially dependent on the muscle-specific chaperone HSPB3
and that depletion of HSPB3 prevents muscle cell differentiation. We further show that HSPB3 binds to LBR in the
nucleoplasm and maintains it in a dynamic state, thus promoting the transcription of myogenic genes, including the
genes to remodel the extracellular matrix. Remarkably, HSPB3 overexpression alone is sufficient to induce the
differentiation of two human muscle cell lines, LHCNM2 cells, and rhabdomyosarcoma cells. We also show that mutant
R116P-HSPB3 from a myopathy patient with chromatin alterations and muscle fiber disorganization, forms nuclear
aggregates that immobilize LBR. We find that R116P-HSPB3 is unable to induce myoblast differentiation and instead
activates the unfolded protein response. We propose that HSPB3 is a specialized chaperone engaged in muscle cell
differentiation and that dysfunctional HSPB3 causes neuromuscular disease by deregulating LBR.
Introduction
Myoblast differentiation is a multistep process regulated
by muscle-specific-regulatory transcription factors (MRFs)
such as MYOD and myogenin (MYOG). MRFs coopera-
tive action induces the expression of muscle-specific
genes, leading to myoblast withdrawal from cell cycle
and cell–cell fusion to form multinucleated myotubes1.
Myoblast differentiation is characterized by remodeling of
the nucleus, cytoskeleton, and extracellular matrix
(ECM)2–4. One of the earliest events is nuclear envelope
(NE) remodeling. The NE is a plastic compartment barrier
responding to mechanical challenges such as cell migra-
tion and nuclei fusion, two typical events of myogenesis2.
During the early steps of cell differentiation, NE compo-
sition, and morphology change, regulating the spatial
segregation of euchromatin and heterochromatin and
influencing gene expression. In cycling myoblasts, the
lamin B receptor (LBR), which binds to LMNB1 and
heterochromatin protein 1 (HP1)5, tethers peripheral
heterochromatin to the NE, inhibiting muscle-specific
gene expression6. In differentiating myoblasts, LBR
expression decreases, as well as its binding to the NE; in
addition, the LBR-tether is partially replaced by the lamin
A/C (LMNA)-tether. This tether switch remodels discrete
peripheral chromatin regions, inducing genes required for
differentiation6. These include genes responsible for
cytoskeleton rearrangement into the specialized con-
tractile cytoskeleton and ECM genes, which sustain cell
migration, cell–cell fusion, and myofibrils assembly6.
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How LBR expression is temporarily coordinated and how
its localization at the NE is spatially modulated during
myoblast differentiation are largely unknown.
Among the muscle-specific genes taking part in muscle
differentiation are those coding for specialized chaperones7.
In C. elegans, the myogenic transcription factor HLH-1
(MYOD) induces the expression of the chaperones hsp-90
and the small heat-shock protein hsp-12.2, which are
required to maintain the folding/assembly of muscle-
specific proteins; conversely, reducing the expression of
these chaperones impairs myogenesis and muscle devel-
opment8. Upon differentiation, murine myoblasts switch
the expression of Hsp90 alpha and the co-chaperone p23 to
Hsp90 beta and Aarsd1L; the Hsp90 alpha/Aarsd1L com-
plex promotes myotube formation9. MYOD induces cha-
perone expression also in mammalian myoblasts, with
HSPB3 standing out as one of the top genes downregulated
in pluripotent cells and acting as differentiation marker10,11.
In agreement, HSPB3 expression is absent in cycling cells
and restricted to few cells, including motoneurons, differ-
entiating myoblasts, fetal brain, and muscles12–14.
HSPB3 belongs to the family of mammalian sHSP
(HSPB), which are ATP-independent chaperones15.
Although structurally similar, the ten HSPBs differ in
terms of chaperone activity, substrate specificity, tran-
scriptional regulation, and expression profile16,17. While
HSPB1/HSPB4/HSPB5 are promiscuous chaperones that
suppress the aggregation of many substrates, the other
members are characterized by either poor chaperone
activity or selectivity toward specific substrates16. Struc-
turally, HSPB3 lacks the C-terminus and has a unique N-
terminal domain, which may account for its moderate
chaperone activity16. Moreover, while HSPB1/HSPB5/
HSPB8 are ubiquitous and can be induced upon stress17,
HSPB3 expression is developmentally regulated11,16.
Finally, while HSPB1/HSPB5/HSPB8 are mainly localized
to the cytoplasm, HSPB3 is also present in the nucleus18.
Thus, HSPB3 may not exert housekeeping and redundant
functions; HSPB3 may act as a muscle-specific chaperone
regulating the folding/function of specialized nuclear
substrates. Although HSPB3 is upregulated by MYOD in
differentiating myoblasts11 and is part of the muscle sig-
nature19, we do not know whether it takes part in the
muscle differentiation program.
Here, we studied whether HSPB3 exerts pro-differentiation
functions using human myoblasts and rhabdomyosarcoma
cells, which are myogenic cancer cells that fail to differentiate
leading to malignant proliferation20.
Results
HSPB3 is enriched at the nuclear envelope
Expression analysis of array data (https://hgserver1.amc.
nl/cgi-bin/r2/main.cgi) shows that HSPB3 has the highest
expression in skeletal muscles (Supplementary Fig. S1A).
HSPB3 is upregulated during myoblasts differentiation
and after MYOD overexpression11. In agreement, ChIP-
seq data showed that MYOD is present on a regulatory
region of the HSPB3 gene in human skeletal muscle
proliferating myoblasts (HSMMs) and its recruitment is
enhanced in differentiated myotubes (HSMMtubes); in
addition, MYOD de novo appeared on a distal regulatory
region of the gene in HSMMtubes and was associated
with enhanced H3K27 acetylation (H3K27ac), indicating
potential active transcription (Supplementary Fig. S1B
and GSE50413 dataset).
Based on these data, we studied HSPB3 expression and
functions in LHCNM2 cells, immortalized human satellite
cells that can undergo myogenic differentiation upon
serum deprivation21. HSPB3 and HSPB2 were absent in
cycling LHCNM2 cells (myoblasts) but were upregulated
in differentiating myoblasts, along with MYOG (Supple-
mentary Fig. S1C, D)11,18. Differentiating LHCNM2 cells
contain a mixture of mononucleated and multinucleated
cells that all expressed HSPB2 and HSPB3; as expected,
the late differentiation marker Myosin Heavy Chain (MyC)
was only detectable in multinucleated cells (Supplemen-
tary Fig. S1D). We refer to this mixed cell population as
differentiating myoblasts. In differentiating myoblasts,
HSPB3 showed a heterogeneous subcellular distribution
(Fig. 1A), similar to HSPB218. In some differentiating
myoblasts, HSPB3 was distributed in the cytoplasm and
nucleoplasm, while in other cells HSPB3 was enriched at
the NE (Fig. 1A). Although HSPB2 and HSPB3 form a
complex22, these two proteins displayed a different loca-
lization in differentiating myoblasts. HSPB2 formed
intranuclear phase-separated condensates;18 HSPB3 was
enriched at the NE and formed nuclear filaments, remi-
niscent of the nuclear lamin meshwork (Fig. 1B). Quan-
tification of endogenous HSPB2 and HSPB3 colocalization
in multinucleated myotubes with HSPB2 foci confirmed
their distinct subcellular pattern (Fig. 1C). As a control,
colocalization of myc and HSPB3 stainings in myoblasts
overexpressing myc-HSPB3 was significantly higher; this
significance was lost by rotating of 90° the red channel
(Fig. 1C). Thus, HSPB2 and HSPB3 exist in separate pools
that may exert distinct functions.
Next, we confirmed colocalization with the NE marker
lamin B1 (LMNB1) of endogenous HSPB3 in differ-
entiating myoblasts (Fig. 1D) and transduced myc-HSPB3
in cycling myoblasts (Fig. 1E). We also observed lamin-
like staining for GFP-HSPB3 in living myoblasts and HeLa
cells (Fig. 1F). Thus, a pool of HSPB3 is enriched at the
NE, independently of cell cycle and cell type.
HSPB3 depletion stabilizes the LBR-tether and impairs
chromocenter reorganization
The LBR-tether replacement with the LMNA-tether
remodels transcription to induce differentiation-specific
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genes upon myoblast differentiation (Fig. 2A). This is
regulated at the expression level: LBR mRNAs are high in
proliferating cells and decrease upon differentiation6.
HSPB3 downregulation decreased MYOG expression in
differentiating myoblasts18 (Fig. 2B). Conversely, compared
to GFP (control), myc-HSPB3 overexpression in cycling
myoblasts, which do not express MYOG, enhanced
MYOG mRNAs (Fig. 2C). We thus measured LBR,
LMNB1, and LMNA expression in cycling and differ-
entiating myoblasts. LBR and LMNB1 mRNAs were
Fig. 1 (See legend on next page.)
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downregulated in differentiating compared to cycling
myoblasts, while LMNA mRNA did not significantly
change (Fig. 2D). Cycling myoblasts overexpressing myc-
HSPB3 downregulated LBR and LMNB1 mRNAs, but not
LMNA mRNA, compared to GFP overexpression (Fig. 2E).
Endogenous HSPB3 depletion in differentiating myoblasts
enhanced LBR and LMNB1 expression, compared to con-
trol cells (Fig. 2F). Thus, modulating HSPB3 levels influ-
ences LBR and LMNB1 expression.
We then studied by microscopy LBR enrichment at the
NE in HSPB3-proficient and HSPB3-deficient differ-
entiating myoblasts. As previously reported6, LBR was
redistributed from the NE to nucleoplasm in differ-
entiating myoblasts infected with a nontargeting shRNA
control; <5% of these cells showed LBR NE enrichment,
which was labeled using an antibody for LMNB1 (Fig. 2G,
H). Upon HSPB3 depletion, LBR was significantly enri-
ched at the NE in >30% of the cells (Fig. 2G, H).
Then, we generated by Crispr/Cas9 technology human
induced pluripotent stem cells (iPSCs) lacking the HSPB3
gene (HSPB3-KO) (Supplementary Fig. S2A). HSPB3-KO
and parental isogenic HSPB3-WT iPSCs were differ-
entiated to skeletal muscle cells (SkMCs) by over-
expressing MyoD and Baf60c23. HSPB3 mRNA was
upregulated after 3 days of differentiation in HSPB3-WT,
but not HSPB3-KO, iPSC-SKMCs (Supplementary Fig.
S2B). Expression of the pluripotency genes NANOG and
OCT4 decreased upon differentiation in both lines (Fig.
2I), similar to LBR and LMNB1 expression. However, LBR
and LMNB1 mRNAs were significantly higher in HSPB3-
KO cells at day 3 compared to HSPB3-WT cells (Fig. 2I).
These results are in agreement with those obtained in
HSPB3-depleted differentiating myoblasts (Fig. 2F).
The LBR to LMNA-tether switch is accompanied by
changes in chromocenter morphology6,24. Chromocenters
are transcriptionally silent DNA repetitive regions origi-
nating from peripheral heterochromatin. During differ-
entiation, chromocenter number decreases and their size
increases (Supplementary Fig. S2C)24,25 (Supplementary
Fig. S2D, E). LBR downregulation is required for chro-
mocenter aggregation upon differentiation6. We thus
studied whether HSPB3 affects chromocenters. HSPB3
upregulation in cycling myoblasts increased chromo-
center aggregation and slightly decreased their size com-
pared to GFP-expressing myoblasts (Supplementary Fig.
S2F, G). Chromocenter number was higher in HSPB3-
depleted myoblasts compared to control cells (Supple-
mentary Fig. S2H). Thus, manipulating HSPB3 affects
LBR expression and distribution, with consequences on
chromocenter organization.
HSPB3 interacts with LBR1-238-GFP and maintains it in a
dynamic state in the nucleoplasm
LBR is an inner nuclear membrane (INM) protein with
a nucleoplasmic N-terminal domain followed by eight
putative transmembrane segments5,26,27. LBR is synthe-
sized in the endoplasmic reticulum (ER) and transits
through the nuclear pore complex (NPC) to the INM. The
first transmembrane region of LBR is sufficient for sorting
to the INM and its N-terminus contains an NLS and an
intrinsically disordered domain that regulate transit
through the NPC28–30.
Alterations of turnover or distribution of INM proteins
affect cell development and functionality and are linked to
cancer, myopathies, and laminopathies31–33. In addition,
LBR accumulation at the NE is associated with defective
myogenesis6. Since LBR targeting to the INM decreases
during differentiation and was affected by HSPB3 deple-
tion, we asked whether HSPB3 may influence LBR nuclear
localization.
Similar to LMNB1, LBR has a long half-life and their
total levels are almost unchanged after incubation of the
cells with the translation inhibitor cycloheximide for
8–16 h in both LHCNM2 and HeLa cells (Supplementary
Fig. S2I, J). As a consequence, LBR turnover is studied
using C-terminal truncated LBR variants32,34. We thus
used a vector coding for the first 238 amino acids of
human LBR and consisting of LBR N-terminus and the
(see figure on previous page)
Fig. 1 HSPB3 is enriched at the nuclear envelope. A Immunofluorescence pictures showing the absence of endogenous HSPB3 (green) in cycling
myoblasts (top panel) and its subcellular distribution in 7-day differentiating human myoblasts (lower panel). DAPI staining is shown. Scale bar=
10 µm. Quantification of HSPB3 subcellular distribution in 7-day differentiating human myoblasts is shown. n= 5 independent experiments, ± s.e.m.
The total number of cells analyzed: 285. B Immunofluorescence pictures showing that HSPB3 (red) does not colocalize with nuclear HSPB2 (green)
foci in differentiating human myoblasts. DAPI staining is shown. Scale bar= 10 µm. C Quantification of HSPB2 and HSPB3 colocalization in
differentiating myoblasts. Pearson’s correlation coefficients (PCCs) of images of Alexa Fluor 488-HSPB2 and Alexa Fluor 594-HSPB3 in 7-day
differentiating myoblasts cells expressing endogenous HSPB2 and HSPB3 (n= 55 multinucleated myotubes). PCCs of images of Alexa Fluor 488-myc
and Alexa Fluor 594-HSPB3 in cycling LHCNM2 cells overexpressing myc-HSPB3 for 24 h, before and after rotating Alexa Fluor 594-HSPB3 image by
90° (n= 47 myoblasts). P < 10-10, +/−s.e.m. D, E 7-day differentiating (D) and cycling (E) human myoblasts were infected with lentiviral particles
expressing myc-HSPB3. Immunofluorescence pictures showing colocalization of myc-HSPB3 with endogenous lamin B1 (LMNB1) filaments and at the
nuclear envelope. DAPI staining is shown. Scale bar= 10 µm. F Overexpressed GFP-HSPB3 (co-expressed at a 1:8 ratio with myc-HSPB3 for 24 h)
shows a NE-like staining in living human myoblasts (left panel) and in fixed (right panel) HeLa cells. DAPI staining is shown. Scale bar= 5 µm. Related
to Supplementary Fig. S1.
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first transmembrane domain, followed by the GFP-tag
(LBR1-238-GFP)
35. LBR N-terminal region contains the
binding sites for LMNB1 and HP1, ensuring its NE
anchorage and retaining its functionality5. Upon over-
expression in cycling myoblasts, LBR1-238-GFP was enri-
ched at the NE, in agreement with previous reports;35 in
cycling cells co-expressing myc-HSPB3, LBR1-238-GFP
redistributed to the nucleoplasm (Supplementary Fig.
S3A). HSPB3 formed nuclear condensates depending on
its overexpression levels; LBR1-238-GFP colocalized with
myc-HSPB3 condensates (Supplementary Fig. S3A). A
similar subcellular distribution of myc-HSPB3 and LBR1-
238-GFP were observed in HeLa cells, where >80% of the
co-transfected cells displayed nucleoplasmic LBR1-238-
GFP (Fig. 3A, B and Supplementary Fig. S3B). By contrast,
co-expression of LBR1-238-GFP with HSPB1 and HSPB7
did not cause its nucleoplasmic redistribution (Fig. 3A, B).
Similar results were obtained when studying the sub-
cellular distribution of endogenous LBR (Supplementary
Fig. S3C).
The condensates formed by overexpressed myc-HSPB3
are reminiscent of assemblies that form via liquid-liquid
phase separation (LLPS) of intrinsically disordered pro-
teins36. HSPB3 N-terminus is disordered37, suggesting
that HSPB3 might undergo LLPS in cells.
First, we co-expressed GFP-HSPB3 and myc-HSPB3 in
cycling-myoblasts and HeLa cells and we followed protein
dynamics by live-cell imaging. In both cell lines, HSPB3
formed dynamic nuclear condensates that touched one
another and coalesced (Supplementary Fig. S3D, E).
Second, we used a HSPB3-deletion mutant lacking the
N-terminus (myc-HSPB3 dN) (Supplementary Fig. S3F).
N-terminus deletion reduced HSPB3 nuclear localization
and its ability to form condensates, which mainly occur-
red inside the nucleus (Supplementary Fig. S3G, H).
We also investigated whether HSPB3-dN influences
LBR1-238-GFP distribution. LBR1-238-GFP (Fig. 3C), as
well as endogenous LBR (Supplementary Fig. S3I), did not
accumulate in the nucleoplasm in cells co-expressing
HSPB3-dN and with cytoplasmic HSPB3-dN. LBR1-238-
GFP could still accumulate in the nucleoplasm of cells
with nuclear HSPB3-dN enrichment (Fig. 3C). We con-
clude that (1) HSPB3 N-terminus promotes its nuclear
accumulation and self-assembly into condensates, (2) only
nuclear HSPB3 affects LBR localization, and (3) once both
proteins are inside the nucleus, the alpha-crystallin
domain of HSPB3 is sufficient to maintain LBR1-238-GFP
in the nucleoplasm.
A deletion mutant of LBR-GFP lacking the transmem-
brane domains cannot bind to the NE and accumulates in
the nucleoplasm, where it displays high mobility34. Third,
we investigated by Fluorescence Recovery After Photo-
bleaching (FRAP) LBR1-238-GFP mobility at the NE in
cells co-expressing mCherry (control) or mCherry-
HSPB3. mCherry-HSPB3 did not prevent LBR1-238-GFP
insertion inside the NE; the pool of LBR1-238-GFP
inserted at the NE displayed low mobility under all con-
ditions tested (Fig. 3D, E). In cells co-expressing mCherry-
HSPB3, LBR1-238-GFP accumulated in the nucleoplasm,
where it was dynamic (Fig. 3D, E). This effect was not cell-
type dependent.
Fourth, using proximity ligation assay (PLA) we found
that myc-HSPB3 associates with LBR1-238-GFP (Fig. 3F).
Fifth, we quantified LBR1-238-GFP localization at NE
and nucleoplasm in cells expressing LBR1-238-GFP alone
or with HSPB3. HSPB3 overexpression decreased the ratio
(see figure on previous page)
Fig. 2 HSPB3 affects LBR levels and distribution in human myoblasts. A Schematic representation showing that the LBR chromatin tether is
replaced by the LMNA chromatin tether during cell differentiation and the impact on myogenic gene expression6. B RT-qPCR analysis of human
differentiating myoblasts infected with lentiviral particles expressing a nontargeting shRNA control sequence (shRNA control) or against HSPB3
(shHSPB3) and differentiated for 5 days following infection. Downregulation of HSPB3 in human differentiating myoblasts decreases the expression of
MYOG (RPLO was used as a housekeeping control gene). n= 3, ± s.e.m.; P= 10−5 (HSPB3); P= 10−3 (MYOG). C RT-qPCR analysis of cycling human
myoblasts infected with lentiviral particles expressing GFP (used as control) or myc-HSPB3 for 7 days and showing that myc-HSPB3 induces the
expression of MYOG (RPLO was used as housekeeping control gene). n= 3, ± s.e.m.; P= 10−5. D RT-qPCR analysis of LBR, LMNB1 and LMNA
expression in 7 days differentiating-myoblasts compared to cycling myoblasts. RPLO was used as a housekeeping control gene. n= 3, ± s.e.m.; P=
non-significant (n.s.). E RT-qPCR analysis of LBR, LMNB1, and LMNA expression in cycling myoblasts overexpressing myc-HSPB3 compared to GFP
(used as control). RPLO was used as a housekeeping control gene. n= 3, ±s.e.m.; P= non-significant (n.s.). F RT-qPCR analysis of LBR, LMNB1, and
LMNA expression in differentiated myoblasts infected with lentiviral particles expressing an shRNA against HSPB3 (shHSPB3) compared to a
nontargeting shRNA control sequence (shRNA control). RPLO was used as a housekeeping control gene. n= 3, ± s.e.m.; P= nonsignificant (n.s.).
G Immunofluorescence pictures showing the subcellular distribution of LBR (red) and mature LMNB1 (8D1 antibody), used as NE marker. LBR (red)
relocalizes from the NE to the nucleoplasm in differentiating human myoblasts expressing a nontargeting shRNA control sequence (shRNA control),
while it is retained at the NE, where it colocalizes with mature LMNB1 upon downregulation of HSPB3 for 5 days. Scale bar= 10 µm. H Upper panel:
automated quantification of LBR at the NE with ScanR. Segmentation of the nucleus (using DAPI staining) and NE is shown. Lower panel:
quantification of LBR NE:nucleoplasm signal ratio at the NE in differentiating human myoblasts control (shRNA control) or HSPB3-depleted (shHSPB3)
is shown (ratio >1.2). n= 3, ± s.e.m.; P= 0.019. Total number of cells analyzed: 864 (shRNA control); 710 (shHSPB3). Scale bar= 10 µm. I RT-qPCR
analysis of NANOG, OCT4, LBR, and LMNB1 expression in HSPB3-WT and HSPB3-KO hiPSCs at two different time points (day 0 and day 3) of skeletal
muscle differentiation. The graphs show the individual values of five independent differentiation experiments and the averages ± standard
deviations. P values are indicated (Student’s t test; paired; two-tailed). Related to Supplementary Fig. S2.
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between NE-embedded and nucleoplasmic LBR1-238-GFP
(Fig. 3G). Myc-HSPB3, but not myc-HSPB1 (control), led
to the accumulation of LBR1-238-GFP in the nucleoplasm
also in motoneuronal-like NSC34 cells (Supplementary
Fig. S3J). Overall, these data suggest that HSPB3 binds to
LBR and maintains it in a dynamic state in the nucleo-
plasm, decreasing its NE-embedding (Fig. 3H).
LBR interacts with LMNB1 and heterochromatin6,38
and HSPB3 colocalizes with LMNB1. We thus tested
whether HSPB3 influences LMNB1 and chromatin
nuclear distribution. By live-cell imaging in HeLa cells
stably expressing GFP-tagged LMNB139, we did neither
observe colocalization of GFP-LMNB1 into HSPB3 con-
densates nor nucleoplasmic redistribution (Supplemen-
tary Video S1). When co-expressed with the chromatin
marker histone H2B-mCherry and GFP-HSPB3 in HeLa
and LHCNM2 cells, GFP-HSPB3 formed condensates that
did not colocalize with H2B-mCherry (Supplementary
Videos S2 and S3). These data suggest that LBR is a novel
and specific substrate of HSPB3.
HSPB3 influences gene expression during myogenic
differentiation
We tested by RNAseq the impact of downregulation
and upregulation of HSPB3 on the global myoblast tran-
scriptome. HSPB3 downregulation altered the expression
of 112 genes (80 genes were downregulated and 32 genes
were upregulated; P <0.01; Supplementary Fig. S4A and
Supplementary Table S1). The ten biological processes
that were negatively regulated by HSPB3 depletion
include skeletal muscle differentiation, structure devel-
opment/function (Fig. 4A). Among the downregulated
genes in HSPB3-depleted myoblasts, we found MYOG,
ACTA1, and DES (Fig. 4B), which we validated by qPCR
(Figs. 2B and 4C).
Compared to GFP, overexpression of myc-HSPB3 in
cycling-myoblasts, in presence of high serum con-
centrations, affected the expression of 381 genes (193
genes were downregulated and 188 genes were upregu-
lated; P < 0.01; Supplementary Fig. S4B and Supple-
mentary Table S2). The ten biological processes that
were positively regulated by HSPB3 overexpression
include extracellular structure organization, connective
tissue development, tissue morphogenesis, and NABA
matrisome-associated proteins (Fig. 4D). NABA matri-
some refers to the genes coding for ECM-associated
proteins40. Interactions between myoblasts and their
ECM are required for muscle development, growth, and
functioning. In addition, skeletal muscles depend on
muscle resident stem cells (satellite cells) to regenerate
throughout their life. Upon damage, ECM remodeling
supports satellite cell activation and differentiation,
enabling muscle repair41,42. It is thus not surprising that
dysregulation of ECM remodeling is linked to muscle
aging and disease42.
Among the genes upregulated following myc-HSPB3
overexpression in cycling-myoblasts, we found those
coding for lumican (LUM), nidogen 2 (NID2), decorin
(DCN) and collagens, key ECM components, as well as
the cell adhesion molecule 1 (CADM1), which regulates
cell–cell and ECM adhesion (Fig. 4E)43. By qPCR, we
confirmed the upregulation of LUM, CADM1, NID2,
and DCN, as well as SVIL and NOTCH3 (Fig. 4F). DCN
upregulation promotes muscle differentiation and
regeneration in vivo44. SVIL (supervillain) regulates the
early assembly of myogenic membrane during
(see figure on previous page)
Fig. 3 HSPB3 displaces LBR from the nuclear envelope to the nucleoplasm. A Immunofluorescence pictures showing the distribution of LBR1-
238-GFP in HeLa cells 48 h after transfection. Co-expression of myc-HSPB1 or V5-HSPB7 does not affect LBR1-238-GFP distribution compared to control
cells, expressing LBR1-238-GFP alone. Myc-HSPB3 displaces LBR1-238-GFP from the NE to the nucleoplasm. Scale bar= 10 µm. B Quantification of
transfected cells from A and showing LBR1-238-GFP at the NE or displaced in the nucleoplasm. n= 3 independent experiments, ± s.e.m. P < 10
−5
between control and myc-HSPB3; P= n.s. between control and myc-HSPB1 or V5-HSPB7. Total number of cells analyzed: LBR1-238-GFP (273); + myc-
HSPB3 (149); + myc-HSPB1 (226); + V5-HSPB7 (129). C Immunofluorescence showing the distribution of LBR1-238-GFP in HeLa cells transfected for
48 h with vectors coding for LBR1-238-GFP alone or with a deletion mutant of HSPB3 that accumulates in the cytoplasm (HSPB3-dN). The blue
arrowhead points to a cell with nuclear HSPB3-dN that displaces LBR1-238-GFP; the white arrowhead points to a cell with cytoplasmic HSPB3-dN that
does not displace LBR1-238-GFP from the NE. Quantitation of LBR1-238-GFP distribution is reported. n= 3 independent experiments, ± s.e.m.; P=
0.004. The total number of cells analyzed: cytosolic;74 nuclear.84 Scale bar= 10 µm. D HeLa cells overexpressing LBR1-238-GFP alone, with mCherry or
with mCherry-HSPB3 +myc-HSPB3 (at a 1:8 ratio) were subjected to fluorescence recovery after photobleaching (FRAP). Pre-bleach, bleach and post-
bleach images of LBR1-238-GFP inserted at the NE and diffusely distributed in the nucleoplasm are shown. E Quantitation of the fluorescence intensity
recovery after bleach of cells treated as described in D. The mean of 12–14 FRAP curves and the fitting curves are shown. sem is shown in gray.
F HeLa cells co-expressing LBR1-238-GFP and myc-HSPB3 were subjected to proximity ligation assay (PLA) using antibodies specific for GFP and HSPB3.
GFP-positive cells were segmented and PLA foci/cell were automatically quantified using ScanR. The average number of PLA foci in cells incubated
with GFP or HSPB3 antibody (used as controls) or with both antibodies is shown. The PLA foci number was normalized for cells incubated with GFP
antibody alone. n= 4 independent experiments, ± s.e.m.; total number cells analyzed/sample: 78–90, P < 0.01. Scale bar= 10 µm. G Left panel:
automated segmentation of the nucleus (using DAPI staining), NE (using LMNB1), and nucleoplasm with ScanR. Scale bar= 10 µm. Right panel:
automated quantification of LBR1-238-GFP NE:nucleoplasm signal ratio in cells expressing LBR1-238-GFP alone (control) or with myc-HSPB3 (+ HSPB3) is
shown. n= 3, ± s.e.m.; P= 0.0018. H Schematic representation of the putative effect of HSPB3 on the LBR-tether, with potential implications on
myogenic gene expression. Related to Supplementary Fig. S3.
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myogenesis45. NOTCH3 participates in the Notch sig-
naling, a well-known regulator of myogenesis and mus-
cle repair. Notch3 induction plays a dual role during
myogenesis: it is induced during the early stages to
generate a temporal lag between myoblast activation by
MYOD and terminal differentiation into myotubes
directed by Mef2c46,47. Of note, HSPB3 downregulation
significantly reduced Notch3 expression in differentiat-
ing-myoblasts, further linking HSPB3 expression with
myogenesis (Fig. 4A).
Conversely, overexpression of HSPB2 in cycling myo-
blasts, in presence of high serum concentrations, did not
Fig. 4 HSPB3 depletion impairs the expression of gene pathways required for myogenesis, while HSPB3 overexpression induces
transcriptional changes that promote myogenesis. A Gene-set enrichment analysis: downregulated genes upon HSPB3 depletion in
differentiating myoblasts. Analysis performed using Metascape Express Analysis on genes highly significant (P < 10−10).80 The top ten hits are shown.
B Volcano plot highlighting that in differentiating myoblasts HSPB3 depletion downregulates the muscle-specific genes coding for myogenin
(MYOG), actin alpha 1 (ACTA1), and desmin (DES), compared to control myoblasts. The horizontal dotted line represents P < 10−5, vertical dotted lines
highlight log2 fold changes of −0.5 and 0.5. Highly significant genes (P < 10−10) with log2 fold change higher than 0.5 (or lower than −0.5) are
marked in red; low significance genes (P > 10−5) with log2 fold change higher than 0.5 (or lower than −0.5) are marked in green; non-significant
genes are marked in gray. C Validation by RT-qPCR of actin alpha 1 (ACTA1) and desmin (DES) downregulation in differentiated HSPB3-depleted
myoblasts compared to control myoblasts. D Gene-set enrichment analysis: upregulated genes upon HSPB3 overexpression in cycling myoblasts.
Analysis performed using Metascape Express Analysis on genes highly significant (P < 10−10). The top ten hits are shown. E Volcano plot highlighting
that HSPB3 overexpression upregulates the matrisome genes LUM, CADM1, NID2, and DCN, as well as the SVIL and NOTCH3 genes, compared to GFP
overexpression, used as a control. The horizontal dotted line represents P < 10−5, vertical dotted lines highlight log2 fold changes of −0.5 and 0.5.
Highly significant genes (P < 10−10) with log2 fold change higher than 0.5 (or lower than −0.5) are marked in red; low significance genes (P > 10−5)
with log2 fold change higher than 0.5 (or lower than −0.5) are marked in green; non-significant genes are marked in gray. F Validation by RT-qPCR of
the genes highlighted in the volcano plot shown in C in cycling myoblast infected with lentiviral particles expressing myc-HSPB3. Related to
Supplementary Fig. S4 and Supplementary Tables S1–3.
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induce the transcriptional program involved in muscle
differentiation (Supplementary Fig. S4C, D and Supple-
mentary Table S3). In particular, HSPB2 overexpression
inhibited the upregulation of the gene pathways that
regulate ECM remodeling, showing an opposite effect
compared to the one of HSPB3 (Supplementary Fig. S4C,
D and Supplementary Table S3).
HSPB3 promotes the differentiation of rhabdomyosarcoma
cells
To further test HSPB3 pro-differentiation effect, we
used cells from fusion-negative rhabdomyosarcoma (FN-
RMS), the most common soft tissue malignant tumor in
children and adolescents, as a model of myogenic-derived
cancer cells48. RMS cells express MYOD and MYOG but
are unable to terminally differentiate in skeletal muscle
cells and proliferate indefinitely49–51.
Using RNAseq, we compared HSPB3 expression levels
in FN-RMS, HSMMs, and HSMMtubes. HSPB3 Frag-
ments Per Kilobase Million (FPKM) were significantly
lower in FN-RMS compared to HSMM, indicating that
HSPB3 expression is downregulated in rhabdomyo-
sarcoma (Fig. 5A).
We then overexpressed myc-HSPB3 in FN-RMS cells for
3 and 10 days and we investigated their ability to differ-
entiate compared to control cells expressing an empty
vector (Fig. 5B). MYOG protein and mRNA levels were
induced upon myc-HSPB3 overexpression for 10 days,
compared to control cells; importantly, cells were cultured
in a growth medium, supplemented with serum (Fig. 5B, C).
MYOG increase was associated to higher levels of the dif-
ferentiation marker Myosin Heavy Chain protein (MyHC;
Fig. 5D) and mRNA (MyH2; Fig. 5E). MYOG and MyH2
increased expression was paralleled by a decreased FN-RMS
cell proliferation rate (Fig. 5F). Thus, HSPB3 overexpression
partly overcame the inhibited transition from a proliferating
myoblast to a postmitotic myocyte of FN-RMS cells.
HSPB3-R116P forms nuclear aggregates that sequester LBR
and WT-HSPB3 and deregulates the muscle transcriptome
Four mutations in the HSPB3 gene have been linked to
distal hereditary motor neuropathy (dHMN) and congenital
myopathy, with unknown mechanisms18,52,53. In particular,
R116P-HSPB3 was identified in a myopathy patient with
altered chromatin distribution and muscle fiber disorganiza-
tion18. We characterized R116P-HSPB3 subcellular distribu-
tion in different cell types. R116P-HSPB3 formed large
nuclear assemblies in HeLa cells (Supplementary Fig. S5A, B).
R116P-HSPB3 assemblies did not colocalize with, but rather
displaced, mCherry-H2B (Supplementary Fig. S5C). R116P-
HSPB3 assemblies formed also in differentiating-myoblasts or
motoneuronal-like NSC34 cells (Supplementary Fig. S5D, E)
and locally inhibited transcription, measured using 5-ethynyl
uridine (Supplementary Fig. S5F).
We then verified R116P-HSPB3 mobility by FRAP. In
contrast to WT-HSPB3, which showed partial mobility
within the condensates (Fig. 6A, upper panel), R116P-
HSPB3 was immobile: thus, R116P-HSPB3 formed
nuclear aggregates (Fig. 6A, middle panel). When co-
expressed with R116P-HSPB3, GFP-tagged WT-HSPB3
was sequestered inside nuclear aggregates (Fig. 6A, lower
panel). Thus, R116P-HSPB3 exerted a dominant-negative
effect on WT-HSPB3.
R116P-HSPB3 nuclear aggregates also sequestered
LBR1-238-GFP in HeLa cells and myoblasts (Fig. 6B, C).
Using FRAP, we observed immobilization of LBR1-238-
GFP inside the R116P-HSPB3 aggregates (Fig. 6D). This
effect is in sharp contrast with the increased nucleo-
plasmic mobility of LBR1-238-GFP observed in cells co-
expressing WT-HSPB3 (Fig. 3D, E).
We then studied how R116P-HSPB3 affects the myo-
blasts transcriptional program. Compared to the muscle
transcriptome of cycling-myoblasts overexpressing GFP
(control), R116P-HSPB3 affected the expression of 695
genes (295 genes were upregulated and 400 genes were
downregulated) (Supplementary Fig. S5G and Supple-
mentary Table S4), while WT-HSPB3 changed the
expression of 381 genes (Supplementary Fig. S5B). When
comparing WT-HSPB3 and R116P-HSPB3 to GFP, the
impact of R116P-HSPB3 on the myoblast transcriptome
was often reversed to the one of WT-HSPB3 (Supple-
mentary Fig. S5G, H). For example, LUM and DCN were
upregulated by WT-HSPB3, while they were down-
regulated by R116P-HSPB3 (P ≤ 10−10, data not shown).
We directly compared the transcriptome of myoblasts
overexpressing R116P-HSPB3 or WT-HSPB3 (Fig. 6E, F).
Many of the gene pathways upregulated by WT-HSPB3
including ECM remodeling and organization, collagen
fibril organization, cell migration (Fig. 4D), were down-
regulated by R116P (Fig. 6E and Supplementary Table S5).
In addition, compared to WT-HSPB3, R116P-HSPB3
overexpression induced the expression of genes involved
in the unfolded protein response, ER stress, and protein
degradation (Fig. 6F).
These results suggest that R116P-HSPB3 loses the
ability to induce the genes involved in ECM remodeling,
while acquiring aggregation-prone properties that can
evoke ER stress, similar to what reported for other pro-
teins that aggregate in the nucleus54,55. This may be
relevant to muscle disease. In fact, muscle exercise and a
high-fat diet evoke chronic ER stress56,57 and the inability
to adapt the ER stress response to environmental changes
and exercise training has been recognized as a patho-
mechanism of congenital myopathies, which are char-
acterized by signs of ER stress in the muscle biopsies58–60.
In agreement, the ultrastructural evaluation of the R116P-
HSPB3-patient’s muscle biopsy showed signs of muscle
degeneration and ER stress: (1) alteration of myofibrillar
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architecture with focal disarrays and loss of cross striation
and Z-band, (2) accumulation of large aggregates of beta-
glycogen particles in intermyofibrillar sarcoplasm and
subsarcolemmal areas, and (3) presence in the sarco-
plasmic reticulum of dilated cisternae resembling round
vacuoles often coalescing (Supplementary Fig. S5I, upper
pictures). In addition, nuclei showed an indented/irre-
gular profile (Supplementary Fig. S5I, lower picture).
Discussion
Here, we provide compelling evidence supporting the
idea that HSPB3 is a specialized chaperone that engages in
Fig. 5 Overexpression of HSPB3 promotes the differentiation of fusion-negative rhabdomyosarcoma (FN-RMS) cells. A Comparative analysis
of HSPB3 fragments per kilo base per million mapped reads (FPKM) in FN-RMS cells (n= 3 cell lines), human skeletal muscle-proliferating myoblasts
(HSMMs), and differentiated myotubes (HSMMtubes) (n= 3 biological replicates), ± s.e.m.. The analysis was performed using publicly available RNA-
seq data: GSE52529 (myoblasts and myotubes); GSE137168 (FN-RMS cell lines). B Representative western blot (n= 3 biological independent
experiments) of protein extracts from FN-RMS control cells and myc-HSPB3 overexpressing FN-RMS cells, 3 and 10 days post-selection. Expression
levels of myc and MYOG were analyzed by immunoblotting. Vinculin was used as a loading control. C Total RNA was extracted from FN-RMS control
cells and from FN-RMS cells infected with lentiviral particles expressing myc-HSPB3 for 3 and 10 days and the expression levels of MYOG were
analyzed by RT-qPCR. n= 3 independent experiments; data are presented as mean value ± SD, Student’s two-tailed t test. Exact P values are reported
in the figure. D Representative immunostaining (n= 3 independent experiments) of FN-RMS control cells and myc-HSPB3 overexpressing cells at
10 days post selection in the growth medium, showing the expression of the differentiation marker MyHC. Nuclei were stained with DAPI. Scale bar
= 75 µm. E The total RNA was extracted from FN-RMS control cells and myc-HSPB3 overexpressing cells at 3 and 10 days post selection and the
expression levels of MyH2 were analyzed by RT-qPCR. n= 3 independent experiments; data are presented as mean value ± SD, Student’s two-tailed
t test. Exact P values are reported in the figure. F Cell confluence is decreased in FN-RMS overexpressing myc-HSPB3 for 3 days compared to FN-RMS
control cells. Cell growth was assessed by confluence analysis using Celigo Cytometer Nexcelom imaging platform at the reported time points. n= 3
independent experiments; data are presented as mean value ± SD, Student’s two-tailed t test. Exact P values are reported in the figure.
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Fig. 6 R116P-HSPB3 forms nuclear aggregates that sequester LBR1-238-GFP and induce a stress response. A HeLa cells were transfected as
follows: GFP-WT-HSPB3 (at a 1:8 ratio with myc-WT-HSPB3, upper panel), GFP-R116P-HSPB3 (at a 1:8 ratio with myc-R116P-HSPB3, middle panel) or
GFP-WT-HSPB3+R116P (at a 1:8 ratio with myc-R116P-HSPB3, lower panel); 24 h post transfection, cells were subjected to fluorescence recovery after
photobleaching (FRAP). Pre-bleach, bleach, and post-bleach images of GFP-WT-HSPB3 (upper and lower panels) and GFP-R116P-HSPB3 (middle
panel) nucleoplasmic foci are shown. Quantitation of the fluorescence intensity recovery after bleach is reported. The mean of 10 FRAP curves for WT-
HSPB3, 13 FRAP curves for R116P-HSPB3 and 13 FRAP curves for WT-HSPB3+R116P-HSPB3 and the fitting curves are shown. s.e.m. is shown in gray.
Scale bar= 10 µm. B Confocal microscopy on HeLa cells expressing LBR1-238-GFP alone or with myc-tagged R116P-HSPB3, using a myc-specific
antibody. Nucleic acid was stained with DAPI. Scale bar= 10 µm. C Confocal microscopy on LHCNM2 cells expressing LBR1-238-GFP alone or with
myc-tagged R116P-HSPB3, using myc and LMNB1 antibodies. Nucleic acid was stained with DAPI. Scale bar= 10 µm. D HeLa cells overexpressing
LBR1-238-GFP with R116P-HSPB3 were subjected to fluorescence recovery after photobleaching (FRAP). Pre-bleach, bleach, and post-bleach images of
LBR1-238-GFP nucleoplasmic foci are shown. Quantitation of the fluorescence intensity recovery after bleach is reported. The mean of 20 FRAP curves
and the fitting curves are shown. s.e.m. is shown in gray. Scale bar= 10 µm. E, F Gene-set enrichment analysis: downregulated (D) and upregulated
(E) genes upon R116P-HSPB3 overexpression in cycling-myoblasts (compared to WT-HSPB3). Analysis performed using Metascape Express Analysis on
genes highly significant (P < 10−10). The top ten hits are shown. Related to Supplementary Fig. S5 and Supplementary Tables S4 and 5.
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muscle differentiation: HSPB3 assists nuclear and chroma-
tin remodeling during myoblast differentiation by targeting
LBR. Deregulation of this HSPB3 specialized function, due
to gene silencing or disease-linked mutation (R116P-
HSPB3), compromised myoblast differentiation, with
implications for human neuromuscular diseases (Fig. 7).
HSPB3 promoted the expression of genes participating
to differentiation in human LHCNM2 myoblasts and
facilitated the differentiation of FN-RMS cells, which fail
to differentiate. Conversely, HSPB3 depletion impaired
the activation of the transcriptional program required for
the buildup of the muscular cytoskeletal apparatus and
ECM remodeling, which regulates cell migration, adhe-
sion, and fusion during myogenesis1,4.
How HSPB3 expression changes affect myoblast dif-
ferentiation? Cell cycle exit and commitment to differ-
entiation are regulated at the transcriptional level and
require chromatin remodeling. In undifferentiated and
embryonic cells, LBR binds to LMNB1 and tethers het-
erochromatin to the INM6. Upon differentiation, the LBR-
tether and LMNA-tether switch6, but how this exactly
occurs is unknown. Most likely, upon cell cycle exit,
quality control mechanisms on pre-existing and newly
synthesized LBR molecules, together with LBR
transcriptional downregulation, contribute to decrease
LBR INM-embedding, indirectly promoting LMNA-
tether organization. However, whether LBR degradation
occurs via the INM-associated degradation pathway or
other pathways is unclear32,61.
LBR is synthesized in the ER surface and reaches the
INM passing through the nuclear pores30,38. Within the
INM, LBR molecules oligomerize and organize in multiple
microdomains that contain immobile oligomerized LBR,
while nonoligomerized LBR is mostly mobile34,62. LBR
oligomerization involves the arginine/serine (RS) region
located in its N-terminus38,62,63. Due to the RS domain,
LBR belongs to the family of intrinsically disordered
proteins, which are prone to misfolding and require
dedicated chaperones to maintain their folding64. Thus,
cells must activate specialized quality control mechanisms
to regulate LBR turnover and avoid its aggregation within
the INM.
Intriguingly, in the presence of HSPB3, LBR1-238-GFP
accumulated in the nucleus, similar to what was reported
for C-terminal truncated LBR variants upon proteasome
inhibition32. Our data suggest that HSPB3 binds to LBR
N-terminus, possibly to the unstructured RS domain.
Since the RS domain regulates LBR self-oligomerization,
and this is associated to LBR aggregation38,62,63, HSPB3
could prevent LBR self-assembly, enhancing its solubility
and limiting its insertion in the NE; this, in turn, may
favor the degradation of newly synthesized LBR, con-
tributing to the gradual loss of the LBR-tether. Of note,
HSPB3 is upregulated upon cell cycle exit, when LBR NE-
embedding decreases. Future efforts should aim at
developing better models to investigate the quality control
of NE-embedded proteins, given their importance in the
regulation of gene expression upon differentiation, and
their association with nuclear envelopathies32,65.
Although we identified an interplay between HSPB3 and
LBR, chromatin associates with the NE via multiple
components, including lamins, LEM-domain proteins,
and DNA-binding factors. We did not find a direct effect
of HSPB3 on LMNB1 and chromatin distribution; yet we
cannot exclude that, besides LBR, HSPB3 might interact
with/regulate the nuclear localization of other NE-
associated proteins. Future research will need to address
how HSPB3 influences NE and chromatin remodeling,
promoting the expression of pro-differentiating genes.
Nonetheless, our study supports a role for HSPB3 as a
myoblast differentiation facilitator, with implications for
disease, including rhabdomyosarcoma (where HSPB3
upregulation may have potential therapeutic value).
Concerning HSPB3-linked diseases, we show that
R116P-HSPB318 aggregates and immobilizes WT-HSPB3
and LBR1-238-GFP, with consequences on myoblast tran-
scriptome. The observed changes include ER stress and
the inability to induce pro-differentiation genes (with
Fig. 7 Schematic model showing how HSPB3 participates to
myoblast differentiation. The replacement of the LBR-tether with
the LMNA-tether remodels transcription to induce differentiation-
specific genes upon myoblast differentiation. HSPB3 assists nuclear
and chromatin remodeling during myoblast differentiation by
targeting LBR (upper panel). Deregulation of this HSPB3 specialized
function, due to gene silencing or disease-linked mutation (R116P-
HSPB3), compromises myoblast differentiation, with potential
implications for human neuromuscular diseases (lower panel).
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local transcription inhibition). ER stress was implicated in
myopathies60, and glycogen clustering occurs during
muscle ER stress;66 thus ER stress may contribute to
muscle degeneration in the patient carrying the R116P-
HSPB3 mutation. Yet, we cannot exclude that gene dys-
regulation due to R116P-HSPB3 loss of function on LBR
and the dominant-negative effect on WT-HSPB3 repre-
sent additional important pathomechanisms. Of note,
satellite cell activation/differentiation and ECM remo-
deling are important to regenerate muscle and neuro-
muscular junctions that can be damaged because of aging
or disease67–69. In addition, HSPB3-linked neuromuscular
diseases develop with aging, when nerve and muscle
regeneration capacities decline70. Thus, by exerting a
dominant-negative effect, R116P-HSPB3 may decrease
the differentiation capacity and regenerative potential of
muscles during aging and in response to muscle damage.
Of note mutations in genes that decrease myoblast dif-
ferentiation, such as dysferlin, were linked to myo-
pathies71. Conversely, mutations in the satellite cell gene
MEGF10, which preserves satellite cells’ undifferentiated/
proliferative potential, deplete the muscle regenerative
capacity and cause myopathy72.
HSPB3 mutations are also linked to dHMNs: HSPB3 may
display a pro-differentiation function in motoneurons, and
deregulation thereof may contribute to dHMNs. Mutations
in genes involved in neuronal/muscular differentiation, and
differentiation defects were linked to dHMNs. For example,
IGHMBP2 leads to differentiation defects in motoneurons
and is mutated in Charcot–Marie–Tooth (CMT) 2S;73
MORC2 is a chromatin-remodeling protein regulating
differentiation and mutated in CMT;74 NDRG1 promotes
differentiation and is mutated in CMT4D;75 Sbf1/Sbf2 are
epigenetic regulators of cell differentiation and are mutated
in CMT76,77.
In summary, our findings pave the way for a better
understanding of HSPB3 implication in the neuromus-




HeLa, HeLa cells stably expressing LMNB1-GFP and
NSC34 cells were maintained in DMEM supplemented
with 100 U/mL penicillin/streptomycin and 10% fetal
bovine serum (FBS) (Sigma) in a humidified atmosphere
at 37 °C with 5% CO2. HeLa cells stably expressing
LMNB1-GFP were generated by Dr. Ina Poser and were
previously described39. LHCN-M2 cells were maintained
in Ham-F12 supplemented with 100 U/mL penicillin/
streptomycin, 20% FBS (Gibco), and 25 ng/mL of rh FGF-
b/FGF-2. For induction of myogenic differentiation,
LHCN-M2 cells were cultured in DMEM supplemented
with 100 U/mL penicillin/streptomycin, and 30 µg/mL
human insulin solution. Cells were routinely tested for
mycoplasma contamination using the MycoAlert kit.
Rhabdomyosarcoma (FN-RMS) cells were obtained from
American Type Culture Collection (Rockville, MD, USA).
Rhabdomyosarcoma cells were cultured in DMEM high-
glucose (Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal bovine serum (FBS), 1% L-glutamine, and
1% penicillin–streptomycin. They were cultured at 37 °C
in a humidified atmosphere of 5% CO2/95% air and reg-
ularly checked for mycoplasma contamination.
Stable HSPB3 knockout (KO) in human iPS KOLF-1
cells (parental cell line obtained by Dr. Tony Hyman from
Dr. Bill Skarnes, Welcome Trust Sanger Institute) were
generated using CRISPR/Cas9 combined with electro-
poration using the Neon 10 μl kit and device (Invitrogen/
ThermoFisher Scientific, Germany) technology. Briefly,
iPS KOLF-1 were cultured in mTeSR1 media (StemCell
Technologies); cells were trypsinized, washed in PBS, and
resuspended in R buffer (Neon kit). Next, a master mix
containing the crRNA pair (for, rev), trRNA (IDT) and
NLS-Cas9 enzyme (purified by the MPI-CBG facility) was
prepared and used for electroporation. Next, pooled cells
were analyzed via genotyping to verify correct modifica-
tion and subsequently selection of stable clones was car-
ried out by picking and genotyping individual clones. The
iPSC KOLF-1 HSPB3 KO clone #18 selected for this study
is a homozygous null mutant lacking exon 1 and is
referred to as HSPB3-KO. iPS KOLF-1 cells parental are
referred to as HSPB3-WT. HSPB3-WT and HSPB3-KO
iPSC KOLF-1 were maintained in Nutristem-XF (Biolo-
gical Industries) containing 0.1% penicillin–streptomycin
(Sigma) in hESC-qualified Matrigel-coated plates
(CORNING) and passaged with 1mg/ml Dispase (Gibco),
as previously described78. For skeletal muscle differentia-
tion, stable lines were generated by the integration of
inducible piggyBac-based expression vectors epB-Puro-
TT-mMyoD and epB-Bsd-TT-hBaf60c, as described23.
Briefly, cells were co-transfected with 2 µg of each vector
and 0.5 µg of the piggyBac transposase using Neon
Transfection System (Invitrogen). Selection was performed
with 0.5 µg/ml puromycin and 2.5 µg/ml blasticidin
(Sigma). To induce differentiation, iPSCs (passage number
10–25) were dissociated to single cells with Accutase
(Gibco) and 250.000 cells were plated in 35-mm dishes in
Nutristem-XF with 0.1% penicillin–streptomycin and
supplemented with the ROCK inhibitor 10 μM Y-27632
dihydrochloride (Enzo Life Sciences) for 24 h, to enhance
survival and adhesion upon dissociation. The next day, the
medium was replaced with Growth Medium (GM; DMEM
high glucose medium, Sigma; 20% FBS North American,
Merk Life Science; 25 ng/ml bFGF, Gibco; 10 ng/ml EGF,
Sigma; 50 μg/ml Insulin, Roche; 1× GlutaMAX, Gibco; 1×
penicillin–streptomycin) in presence of 200 ng/ml dox-
ycycline (Sigma). This is considered day 0. At day 1, the
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medium was replaced with differentiation medium (Ske-
letal Muscle Cell Differentiation Medium, Promocell; 1×
penicillin–streptomycin, Sigma) in presence of 200 ng/ml
doxycycline. Cells were collected at day 0 and day 3 for
RNA analysis.
Cell growth analysis
Cell growth was assessed by confluence analysis using
Celigo Cytometer Nexcelom imaging platform at the
reported time points.
DNA transfection
HeLa cells were lipofected using Lipofectamine 2000
(Life Technologies), while NSC34 and LHCNM2 cells
were lipofected using Lipofectamine 3000 (Life Technol-
ogies) following the manufacturer’s instructions. Cells
were processed for protein or RNA analysis 48 h post-
transfection, unless otherwise indicated.
Viral vector production and lentiviral vectors
Lentiviral particles for GFP, myc-HSPB3, and myc-
R116P were produced using Lenti-Pac HIV Expression
Packaging Kit, following the manufacturer’s instructions,
as previously described18. shRNA Control and shRNA
HSPB3 lentiviral particles were generated using GIPZ™
Lentiviral shRNA according to the manufacturer’s
instructions as previously reported18. Briefly, for viral
transduction with lentiviral particles encoding for GFP,
HSPB2, myc-HSPB3 and myc-R116P, cycling LHCNM2
cells were seeded at 5 × 105 cells/six-well plate. Twenty-
four hours after seeding, the cell culture medium was
replaced with 1 mL of viral suspension supplemented
with 8 μg/mL of polybrene and incubated for 16 h at
37 °C. Cells were then harvested with trypsin, seeded in a
T25 flask or in 24-well chambers at 1.2 × 105 cells/well
and incubated for 48 h in a growth medium. Then,
infected cells were selected by adding a fresh growth
medium supplemented with 4 μg/ml puromycin. Cells
were harvested or fixed after 4 days of selection, unless
otherwise indicated. For viral transduction with lentiviral
particles for shRNA Control and shRNA HSPB3, cycling
LHCNM2 cells were seeded at 5 × 105 cells/six-well or
1.2 × 105 cells/-24-well plate. Twenty-four hours after
seeding, the cell culture medium was replaced with 1 mL/
six-well or 250 µL/24-well of viral suspension supple-
mented with 8 μg/mL of polybrene and incubated for 16 h
at 37 °C; cycling media was then added to a final volume
of 2 mL/six-well or 500µL/24-well. Infected cells were
selected by adding fresh growth medium supplemented
with 4 μg/ml puromycin. After 4 days of selection with
puromycin, cells were then incubated with a differentia-
tion medium supplemented with 4 μg/mL puromycin for
5 days. Cells were then harvested or fixed, with media
being replaced every 2 days.
RNA Isolation, RT-qPCR, and RNA-Seq and computational
analysis of sequencing data
RNA isolation and RT-qPCR on HeLa cells, LHCNM2
cells, FN-RMS cells, and iPSCs, as well as primer
sequences, are described in the Supplementary Section.
For RNAseq analysis, LHCNM2 total RNA was
extracted as described above. Libraries were prepared
using the TruSeq Stranded mRNA Library Prep Kit.
Library preparation started with 1 μg of total RNA.
After selection (using poly-T oligo-attached magnetic
beads), mRNA was purified and fragmented using
divalent cations under elevated temperature. The RNA
fragments underwent reverse transcription using ran-
dom primers followed by second strand complementary
DNA (cDNA) synthesis with DNA Polymerase I and
RNase H. After end repair and A-tailing, indexing
adapters were ligated. The products were then purified
and amplified (20 μl template, 14 PCR cycles) to create
the final cDNA libraries. After library validation and
quantification (Agilent 2100 Bioanalyzer), equimolar
amounts of library were pooled. The pool was quanti-
fied by using the Peqlab KAPA Library Quantification
Kit and the Applied Biosystems 7900HT Sequence
Detection System. The pool was sequenced on an Illu-
mina HiSeq 3000 sequencer with a paired-end (2 × 75
bp) protocol.
RNA-seq data were analyzed using a SnakePipes
pipeline (https://snakepipes.readthedocs.io/en/latest/).
Raw counts (output of SnakePipes RNA-seq module)
were used as input for DESeq2. FPKMs, FC, and P values
were calculated with DEseq2 using default parameters
(https://bioconductor.org/packages/release/bioc/html/
DESeq2.html).
For gene expression analysis in rhabdomyosarcoma
cells, the total RNA was extracted using TRIzol (Invi-
trogen, Carlsbad, CA, USA) according to the manu-
facturer’s protocol. Reverse transcription was performed
using the Improm-II Reverse Transcription System
(Promega, Madison, WI, USA). The expression levels
were measured by real-time RT-qPCR for the relative
quantification of the gene expression. An Applied Bio-
systems 7900HT Fast RealTime PCR System (Applied
Biosystems) was used for the measurements. The
expression fold change was calculated by the 2-ΔΔCt
method for each of the reference genes.
For gene expression analysis in iPSCs, total RNA was
extracted with E.Z.N.A. Total RNA Kit (Omega bio-tek)
and retrotranscribed with iScript Reverse Transcription
Supermix for RT-qPCR (Bio-Rad). Target genes were
analyzed with iTaqTM Universal SYBR Green Supermix
(Bio-Rad). The internal control used was the house-
keeping gene ATP5O (ATP synthase, H+ transporting,
mitochondrial F1 complex, O subunit). Primer sequences
are reported in the key resource table.
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Protein extract preparation and western blotting
For HeLa and LHCNM2 cells: cells were harvested and
lysed in Laemmli buffer (2%) with 4M urea and homo-
genized by sonication for 5 s. Protein samples were reduced
with β-mercaptoethanol (final 3–5%) and boiled for 3min
at 100 °C before migration on SDS-PAGE gels and trans-
ferred onto the nitrocellulose membrane. Nuclear and
cytoplasmic fractions of HeLa and LHCNM2 were pre-
pared by homogenizing the cells in lysis buffer (10mM
HEPES pH 7.9, 10mM KCl, 0.1mM EDTA, 0.1mM
GDTA, 1mM DTT, 0.15% nonidet 40, 1% Phosphatase
Inhibitor Cocktail 1×), using a 26G needle followed by
sonication for 5 s. Lysates were centrifuged at 12,000×g for
30 s, separating the supernatant (cytoplasmic fraction) and
the pellet (nuclear fraction), which was resuspended in
Laemmli buffer (2%); Laemmli buffer to a final con-
centration of 2% SDS was added to the supernatant. Pro-
tein samples were reduced with β-mercaptoethanol (final
3–5%), boiled for 3min at 100 °C, and processed as
described above.
Membranes were blocked with PBS-T (137mM NaCl,
2.7 mM KCl, 10 mM sodium phosphate dibasic, 2 mM
potassium phosphate monobasic, 0.1% Tween-20 Bio-
Rad, pH 7.4) and 5% dried non-fat milk for 1 h at room
temperature. Primary antibodies diluted in PBS-T con-
taining 3% BSA and 0.02% Na-azide were added and
incubated overnight at 4 °C. HRP-conjugated secondary
antibodies were prepared in PBS-T and 3% dried non-fat
milk and incubated for at least 1 h at room temperature.
Protein signals were visualized using either ECL kit
Westar Eta C Ultra 2.0 or ECL kit Westar Supernova.
Chemiluminescence signals were acquired on a Chemi-
Doc imaging system.
For rhabdomyosarcoma cells: Western blotting was
performed on whole-cell lysates by homogenizing cells in
RIPA lysis buffer (50 mM Tris pH 7.4, 150mM NaCl, 1%
Triton X-100, 1 mM EDTA, 1% sodium deoxycholate,
0.1% SDS), containing the protease inhibitor cocktail
(Sigma, St Louis, MO, USA), NaF 1mM, Na3VO4 1mM
and PMSF 1mM. Lysates were incubated on ice for
30min and centrifuged at 12,000×g for 20 min at 4 °C.
Supernatants were then quantified with BCA Protein
Assay Kit (Pierce, Life Technologies, Carlsbad, CA, USA)
according to the manufacturer’s protocol and then boiled
in reducing SDS sample buffer (200 mM Tris–HCl pH
6.8, 40% glycerol, 20% β-mercaptoethanol, 4% sodium
dodecyl sulfate, and bromophenol blue); and 30 μg of
protein lysate per lane was run through 12% SDS-PAGE
gels, and then transferred to Hybond ECL membranes
(Amersham, GE HEALTHCARE BioScience Corporate
Piscataway, NJ, USA). Membranes were blocked for 1 h in
5% nonfat dried milk in Tris-buffered saline (TBS) and
incubated overnight with the appropriate primary anti-
body at 4 °C. Membranes were then washed in TBS and
incubated with the appropriate secondary antibody. Both
primary and secondary antibodies were diluted in 5% non-
fat dried milk in TBS. Membranes were then incubated
with HRP-conjugated secondary antibody for 1 h at room
temperature. Detection was performed by ECL Western
Blotting Detection Reagents (Amersham, GE HEALTH-
CARE BioScience Corporate Piscataway, NJ, USA). The
antibodies used in the study are reported in the key
resource table.
All images were analyzed with ImageLab analysis tools,
and signal intensities measured and normalized to the
loading control.
Immunofluorescence on cultured cells and proximity
ligation assay
HeLa cells were grown on polylysine-coated glass cov-
erslip coated with poly-L-lysine (P8920; Sigma), while
LHCNM2-cells were grown on SPL cell culture chambers
(330068; Biosigma). After washing with cold PBS, cells
were fixed with 3.7% formaldehyde in PBS for 9 min at
room temperature, followed by permeabilization with ice-
cold acetone for 5 min at −20 °C. PBS containing 3% BSA
and 0.1% Triton X-100 was used for blocking and incu-
bation with primary and secondary antibodies.
Rhabdomyosarcoma cells were fixed after 10 days post
selection in 4% paraformaldehyde (PFA)/PBS for 10min,
permeabilized in 0.5% Triton X-100/PBS, and blocked
with 4% BSA in PBS 1 h at room temperature. Immu-
nostaining with anti-MyHC antibody (MF-20, 1:20;
DSHB, University of Iowa, Iowa City, IA, USA) was per-
formed 1 h at room temperature. Antibody binding was
revealed using species-specific secondary antibodies cou-
pled to Alexa Fluor 488. Nuclei were visualized by
counterstaining with DAPI. Images were acquired with a
Leica microscope.
Proximity ligation assay was performed with the Duo-
link™ In Situ Red Kit, using GFP and HSPB3 antibodies
following the manufacturer’s instructions. The antibodies
used in the study are reported in the key resource table.
Image analyses
Images were acquired by confocal microscopy of fixed
samples using a Leica TCS SP8 microscope (Leica
Microsystems) equipped with a White Light Laser and
with a ×63 oil-immersion lens; scanning speed was 400 Hz
and pixel resolution was 1024 × 1024. For cellular dis-
tribution analysis, fields were randomly selected and
confocal images were analyzed using the ScanR software
(Olympus) or manually assessed for nuclear and/or
cytoplasmic enrichment.
LBR enrichment at the nuclear rim was performed using
the ScanR software (Olympus). Briefly, nuclei were seg-
mented based on DAPI signal using an intensity detection
algorithm. The LMNB1 (8D1) signal detection at the
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nuclear rim was performed by applying a fixed distance in
pixels from the segmented nucleus. Similar fixed distance
was applied to measure fluorescence intensity inside the
nucleus (nucleoplasm). The mean fluorescence intensity
of LBR was measured at the rim and inside the nucleo-
plasm. The relative enrichment of LBR at the rim was
calculated as a ratio of mean fluorescence intensity at the
rim divided by mean intensity in the nucleoplasm. From
the values obtained ratios of above 1.2 were considered as
“Nuclear envelope enriched” whereas ratio under 1.2 were
considered as “diffuse in the nucleus”.
Chromocenter analysis was performed on confocal
microscopy images composed of 0.3-μm Z-stacks spanning
the whole nucleus, determined by DAPI staining and with
the ImageJ Fiji NucleusJ plugin79. Briefly, images were first
segmented using Nucleus Segmentation (batch mode) set-
ting the Voxel Calibration at x= 0.075, y= 0.075, z= 0.029,
units= pixel; volumes set as Min Volume= 7, Max
Volume= 2000 and Stack Histogram 99.5%.
Quantification of PLA foci was performed on 1-μm Z-
stack images using the ScanR software (Olympus); cells
were segmented based on the LBR1-238-GFP signal and
the intensity detection algorithm. Cells stained with anti-
GFP only, anti-HSPB3 only or no antibodies were used as
controls; cells stained with anti-GFP only were used for
normalization.
Live-cell imaging and fluorescence recovery after
photobleaching (FRAP)
FRAP measurements on HeLa cells transfected with
LBR1-238-GFP in presence of the absence of mCherry-
HSPB3 were performed using a confocal microscope
Leica TCS SP8 (Leica Systems), while FRAP measure-
ments on GFP‐PSMA7 HeLa Kyoto cells were performed
using the Leica SP8 system.
For FRAP analysis, we used a ×63 oil immersion
objective. A region of ~2.2–2.5 × 2.2–2.5 μm was bleached
for 1 s using a laser intensity of 100% at 405 nm. For FRAP
analysis of untreated cells or in cells during the stress
recovery in a drug‐free medium, a laser intensity of 100%
for 5 s was used. Recovery was recorded for 300 time
points after bleaching (300 s). Analysis of the recovery
curves was carried out with the FIJI/ImageJ. The flow of
the protein was measured by quantifying the recovery of
the bleached area at the cost of the unbleached region and
using a custom-written FIJI/ImageJ routine. The bleached
region was corrected for general bleaching during image
acquisition. We quantified the molecules that move from
the unbleached region to the bleached region, leading to
the recovery of the bleached region.
Prior to FRAP analysis, we corrected the images for drift
using the StackReg plug‐in function of the FIJI software
suite. The equation used for FRAP analysis is as follows
((Ibleach− Ibackground)/(Ibleach(t0)− Ibackground
(to)))/((Itotal− Ibackground)/(Itotal(t0)− Ibackground
(to))), where Itotal is the fluorescence intensity of the
entire cellular structure, Ibleach represents the fluores-
cence intensity in the bleach area, and Ibackground the
background of the camera offset. FRAP curves were
averaged to obtain the mean and standard deviation.
Fluorescent density analysis was performed using FIJI/
ImageJ and selecting specific region of interest (ROI).
Transmission electron microscopy (TEM)
A small fragment of muscle biopsy was taken to per-
form ultrastructural analysis. The specimen was fixed in a
0.1M Cacodylate buffered solution of 2.5% of glutar-
aldehyde, post-fixed in 1% osmium tetroxide in the same
buffer, dehydrated in graded ethanol, and embedded in
Araldite. Thin sections, counterstained with uranyl acet-
ate and lead citrate were observed under a Philips 410
Transmission Electron Microscope.
Quantification and statistical analysis
One-way ANOVA followed by Bonferroni–Holm post
hoc test was used for comparisons between three or more
groups. Student’s t test was used for comparisons between
two groups. Where specified Kruskal–Wallis test was
used for comparison between non-normally distributed
data. Unless otherwise indicated, *P < 0.05, **P < 0.01, and
***P < 0.001. For RNA-seq data, FC, and P values were
calculated with DEseq2.
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